Genenta Science S.P.A. ADR (GNTA)

$4.04 +0.12 (3.06%)
Market Cap 66.03M
Revenue (ttm) 0.00
Net Income (ttm) -9.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,100
Avg Vol 23,712
Day's Range N/A - N/A
Shares Out 18.29M
Stochastic %K 75%
Beta 0.66
Analysts Strong Sell
Price Target $23.00

Latest News on GNTA

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Apr 15, 2025, 5:00 AM EDT - 12 days ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Mar 19, 2025, 9:28 AM EDT - 5 weeks ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 28, 2025, 8:01 AM EST - 3 months ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 9, 2025, 6:00 AM EST - 3 months ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 8, 2025, 3:17 PM EST - 3 months ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024, 7:00 AM EDT - 6 months ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 7 months ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 8, 2024, 5:00 AM EST - 1 year ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023, 3:00 AM EDT - 1 year ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023, 7:00 AM EDT - 1 year ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 2, 2023, 6:45 AM EST - 2 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 7, 2023, 7:00 AM EST - 2 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 7, 2022, 8:05 AM EST - 2 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022, 7:30 AM EDT - 2 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Investor Conferences

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022, 6:00 AM EDT - 2 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022, 7:30 AM EDT - 3 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 9, 2022, 7:30 AM EDT - 3 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 3 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 4, 2022, 7:30 AM EDT - 3 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 2, 2022, 4:30 PM EDT - 3 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 3 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022, 7:30 AM EDT - 3 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 9, 2022, 7:46 AM EST - 3 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 3 years ago

Genenta to Participate at Upcoming Investor Conferences

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021, 4:15 PM EST - 3 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 3 years ago

Genenta Announces Pricing of Upsized Initial Public Offering